Activated Charcoal Antimony Trisulfide Bismuth Sub

證據等級: L5

預測適應症: 0 個

Multi-Component Preparation (15 Ingredients): Insufficient Data for Repurposing Evaluation

One-Sentence Summary

This submission contains a 15-ingredient multi-component preparation (including Activated Charcoal, Dopamine, Human Epidermal Growth Factor, Silver Nitrate, and various botanical/animal-derived substances) with no established regulatory indication and no DrugBank identifier.

The TxGNN model returned no repurposing predictions for this compound, and no clinical trials or literature evidence are available.

This evaluation cannot proceed beyond the data-gathering stage without first resolving the identity and regulatory status of this preparation.

Quick Overview

Item	Content
Original Indication	Unknown — no regulatory records found
Predicted New Indication	None — TxGNN returned no predictions
TxGNN Prediction Score	N/A
Evidence Level	L5 (model prediction only — and even this is absent)
Market Status	Not marketed (0 authorizations)
Number of NDAs	0
Recommended Decision	Hold

Why No Prediction Is Available

The 15-ingredient formula contains a highly heterogeneous mix of pharmacological categories:

Gastrointestinal agents: Activated Charcoal, Bismuth Subnitrate, Ipecac, Sus Scrofa Stomach
Cardiovascular: Dopamine
Growth factors / Wound healing: Human Epidermal Growth Factor
Antimicrobials: Silver Nitrate, Oregano, Semecarpus Anacardium Juice
Botanicals / Traditional medicine: Dioscorea Villosa Root, Momordica Balsamina Immature Fruit, Picea Mariana Resin, Robinia Pseudoacacia Bark
Heavy metals / Minerals: Antimony Trisulfide, Bismuth Subnitrate, Silver Nitrate
Animal-derived: Sus Scrofa Stomach, Sus Scrofa Sympathetic Nerve

This combination resembles a homeopathic or traditional compound preparation rather than a single chemical entity. TxGNN is trained on single-agent DrugBank entries; without a DrugBank ID, the model cannot map this preparation to a node in the knowledge graph, which explains the absence of any prediction output.

Without a recognized mechanism of action or disease target, any repurposing analysis would be speculative.

Safety Considerations

Please refer to the package insert for safety information.

Note: Several ingredients in this preparation carry known individual safety concerns that warrant attention even in the absence of formal DDI data:

Ipecac: use has been largely discontinued due to risk of cardiomyopathy and aspiration

Antimony Trisulfide: antimony compounds are nephrotoxic and hepatotoxic at systemic exposure

Silver Nitrate: caustic; systemic absorption risk (argyria)

Semecarpus Anacardium: contains urushiol-related allergens; contact sensitizer

Conclusion and Next Steps

Decision: Hold

Rationale: This preparation could not be evaluated because TxGNN produced no predictions, no regulatory authorization exists in any jurisdiction, and the multi-ingredient heterogeneous composition cannot be matched to a DrugBank knowledge graph entry. There is no evidence base (clinical trials or literature) linking this specific combination to any new indication.

To proceed, the following is needed:

Drug identity resolution — Determine whether this preparation has a recognized brand name, a pharmacopoeial monograph, or a homeopathic registration number; submit a single INN or a structured multi-ingredient NDA filing number
Regulatory status clarification — If this is a homeopathic or traditional medicine, document under which regulatory category (e.g., TFDA 中藥、成藥, or homeopathic exemption) it would be reviewed
DrugBank mapping — Identify the primary active component(s) for individual DrugBank lookup, enabling TxGNN to generate predictions on the lead molecule(s)
MOA documentation — Provide a proposed mechanism of action for the preparation’s intended therapeutic effect; this is required before any repurposing rationale can be constructed
Safety review — Obtain or reconstruct a package insert for each active ingredient; several components (Ipecac, Antimony Trisulfide, Silver Nitrate) have well-documented toxicity profiles that must be formally assessed before any repurposing study is initiated
Re-submit as single-agent candidates — If repurposing evaluation is the goal, consider splitting the preparation and submitting each pharmacologically active ingredient (e.g., Dopamine, Human Epidermal Growth Factor) as separate Evidence Pack entries
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.